The Cystic Fibrosis Foundation is investing up to $15 million in ReCode Therapeutics to support the development of…
Articles by Marisa Wexler, MS
A novel inhaled antibiotic that Spexis is developing to treat infections of Pseudomonas aeruginosa — the key bacterial agent of lung…
The Phase 1b/2a clinical trial SWARM–Pa, testing Armata Pharmaceuticals‘ experimental phage therapy AP-PA02 in people with cystic fibrosis…
Claire’s Place Foundation has announced the launch of its fundraising campaign, called #CPFoneinamillion, to support families with…
People with cystic fibrosis (CF) who are treated with Orkambi and Symkevi (Symdeko) in real-world settings tend…
First Wave BioPharma has asked the U.S. Food and Drug Administration (FDA) for permission to start a Phase 2…
A novel gene-editing tool that allows scientists to “drag-and-drop” sequences of DNA into the genome, without inducing large cuts, could…
Vertex Pharmaceuticals recently filed an application with the U.S. Food and Drug Administration (FDA) asking that Trikafta, its…
A new test that measures the excretion of bicarbonate in urine may be used to assess the effectiveness of treatments…
Differences in levels of proteins related to wound healing, cell migration and neurological development may influence whether or…